Stockreport

Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF 16, with deeper responses by week 24 including about PASI 90 ~65% and PASI 100 just over 40% , and clinical separation from placebo emerging as early as week 4. The Ph [Read more]